Catalyst Wire Dossier Catalyst Wire Dossier

Dolutegravir/Emtricitabine/Tenofovir Disoproxil Fumarate

Dolutegravir/emtricitabine/tenofovir disoproxil fumarate · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Dolutegravir/Emtricitabine/Tenofovir Disoproxil Fumarate, covering 2023-03-15 to 2023-03-15. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults [Phase 3]

See pricing